From 2013 to 2023, China's hormones in dosage market saw consistent growth, starting from $2.85 per capita in 2013 to $5.74 per capita in 2023. The growth trend appeared steady, with notable annual increases between 2016 and 2017, and 2020 and 2021. However, growth slowed between 2021 and 2022, likely due to market saturation or economic challenges, but rebounded slightly in 2023.
Year-on-year growth, focusing on 2022 to 2023, was about 3.6%. The five-year CAGR from 2019 to 2023 was approximately 3.2%, indicating moderate market expansion.
Future trends to watch:
- Increased aging population demand could drive market expansion.
- Policy changes or healthcare funding may influence growth potential.
- Technological innovations could lead to more market entries.
